Enlicitide Adds an Oral Option for Hypercholesterolemia

I kept a notebook beside me while I read the FDA material. One page says oral PCSK9 inhibitor. The facing page says no cardiovascular outcomes claim. I returned to those two lines because they hold the useful news and its limit: enlicitide joins the treatments available when the statin therapy a person can tolerate has not lowered LDL-C enough, while offering something the other PCSK9-directed medicines do not.

It is taken by mouth.

Until this approval, PCSK9 inhibition had depended mainly on injectable monoclonal antibodies or an injectable small interfering RNA therapy. A tablet may appeal to people who dislike injections or have trouble with storage and training. Oral does not always mean easy, though. What enlicitide looks like in daily care will depend on the label, side effects, insurance coverage, cost and whether people keep taking it.

The LDL-C effect behind the decision

The FDA based its decision on additional LDL-C lowering in adults who were already receiving lipid-lowering treatment. Enlicitide is approved for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, who still need a further reduction while taking the statin therapy they can tolerate.

The phase 3 program described by the agency included randomized, double-blind comparisons with placebo. The larger hypercholesterolemia trial enrolled 2,912 adults. The heterozygous familial hypercholesterolemia trial enrolled 303. Both measured the primary lipid result at 24 weeks.

I underlined 24 weeks in the notebook, not because the interval is unusually short for seeing whether LDL-C moves, but because it cannot tell us what happens to heart attacks, strokes or survival after years of treatment.

Those percentages are laboratory results. They are not cardiovascular outcomes. The FDA announcement did not include confidence intervals or p-values for the estimates, so I cannot supply them here, and the approval record cited for this brief did not report a demonstrated reduction in myocardial infarction, stroke, cardiovascular death or death from any cause.

The notebook page had room for both numbers. It still had no outcomes result to put beside them.

Earlier randomized phase 2b research studied MK-0616, the development name for enlicitide, for eight weeks in adults with hypercholesterolemia who used a range of background lipid-lowering therapies. LDL-C reductions increased with dose. The study helped show that oral PCSK9 inhibition could lower cholesterol, but eight weeks of laboratory measurements could not answer a question about long-term cardiovascular outcomes.

How an oral PCSK9 inhibitor works

PCSK9 promotes the breakdown of LDL receptors on liver cells. Blocking PCSK9 allows more of those receptors to return to the cell surface, where they can clear circulating LDL particles. Enlicitide is an oral macrocyclic peptide designed to disrupt the interaction between PCSK9 and the LDL receptor.

The target is familiar. The tablet is new.

Injectable PCSK9 monoclonal antibodies have produced large LDL-C reductions, and major outcomes trials have found lower cardiovascular event rates with some of them. Evolocumab reduced major cardiovascular events among patients with established atherosclerotic cardiovascular disease in FOURIER. Alirocumab improved cardiovascular outcomes after acute coronary syndrome in ODYSSEY OUTCOMES.

That history gives clinicians a reason to take the target seriously, but it does not let anyone copy those findings into the enlicitide column. Medicines directed at the same pathway can differ in exposure and adverse effects, while a daily tablet may be taken less consistently outside a trial than a periodic injection. Enlicitide needs direct evidence from an outcomes trial that is large enough and continues long enough to detect whether cardiovascular events fall.

I drew no arrow between the injectable results and the blank line in the notebook. The evidence does not support one.

Where enlicitide may fit in practice

The clearest role is as added treatment for adults whose LDL-C remains above an individualized threshold despite maximally tolerated statin therapy. That includes people with heterozygous familial hypercholesterolemia, who may have had elevated LDL-C from birth and often need more than one medicine to lower it enough.

How the drug is taken will change some office conversations. One person may prefer a tablet to self-injection. Someone else may find a periodic injectable easier because the pill organizer already holds medicines for other chronic conditions, and another daily tablet becomes one more thing to remember after the trial visits are over. The prescribing information matters, especially if food timing or missed tablets can affect exposure.

Clinicians cannot assume this medicine behaves like an ordinary pill just because it comes as one.

Statins remain the foundation of treatment. They have extensive evidence for preventing cardiovascular events and are the background therapy specified for the population emphasized by the FDA. Enlicitide adds another option for residual LDL-C elevation in a field that already includes oral nonstatin medicines as well as injectable therapies directed at PCSK9.

The choice will depend partly on how much more LDL-C lowering a person needs and whether an earlier treatment caused tolerability problems. Coverage matters. The burden of taking the medicine day after day does too, although that burden will not look the same for every patient.

The placebo-adjusted reductions of 55.8% and 59.4% suggest an effect in the range associated with intensive PCSK9 inhibition. The approval studies compared enlicitide with placebo, however, and they did not establish that it works better than another nonstatin medicine.

Important gaps after approval

The largest open question is cardiovascular events. LDL-C is a validated treatment target, and a broad body of evidence supports lowering it to reduce atherosclerotic risk, but the benefit attached to one medicine depends on who receives it, how far LDL-C falls and whether treatment continues over years. A lipid measurement at 24 weeks cannot answer all of that.

The public FDA announcement also cannot stand in for the full prescribing information or the agency’s detailed review materials. It does not provide enough information to independently examine every planned subgroup or uncommon adverse event. Interactions are not fully described there. Neither are all the reasons participants stopped treatment.

Longer follow-up matters for a medicine intended for chronic use.

There is another gap, the one between a controlled trial and a pill organizer on a bathroom counter. Trial participants may follow administration instructions more consistently than people who are managing chronic illnesses while insurance changes, prescriptions accumulate and a tablet that seemed manageable at first becomes easier to miss. Those pressures can alter adherence and persistence after approval.

The phase 2b study was funded by industry. Sponsorship and investigator conflicts belong in the interpretation. Randomization and placebo control reduce familiar sources of bias, but they do not make those disclosures irrelevant.

By this point, the notebook had accumulated figures and caveats, yet the facing-page arrangement had not changed. LDL-C lowering sat on one side. Cardiovascular outcomes remained on the other.

Questions clinicians ask

Does approval mean enlicitide prevents heart attacks and strokes?

No. Approval establishes that enlicitide lowers LDL-C in the indicated population. The FDA record cited here does not report a demonstrated reduction in myocardial infarction, stroke or cardiovascular death, and those outcomes should not be attributed to enlicitide without direct trial evidence.

Who is the most obvious candidate for this oral therapy?

The evidence applies most directly to adults with hypercholesterolemia who need additional LDL-C lowering despite maximally tolerated statin therapy, including adults with heterozygous familial hypercholesterolemia. Choosing enlicitide rather than another nonstatin treatment will depend on the reduction needed, the person’s preferred way of taking medicine, the label’s safety information and access.

Can cardiovascular outcomes from injectable PCSK9 inhibitors be extrapolated?

No. Those trials provide strong evidence that PCSK9 inhibition and substantial LDL-C lowering can reduce events in certain high-risk populations. They do not prove an outcomes benefit for enlicitide. Formulation and exposure differ among medicines, and people who continue taking a daily tablet may differ from those who remain on a periodic injectable.

Does an oral formulation necessarily improve adherence?

Not necessarily. Avoiding injections removes a real barrier for some adults. Daily treatment asks them to remember another tablet and follow any administration requirements in the label. Evidence collected after approval will show whether oral delivery improves persistence, LDL-C control and access in routine US care.

The notebook remains open: 55.8% and 59.4% on one page, with the cardiovascular outcomes line blank on the other.

Questions people ask

How much did enlicitide lower LDL cholesterol in the trials?

The reviewed phase 3 trials found placebo-adjusted LDL-C reductions of 55.8% in adults with hypercholesterolemia and 59.4% in those with heterozygous familial hypercholesterolemia. Both primary measurements were taken at 24 weeks.

Does enlicitide prevent heart attacks or strokes?

The FDA record reviewed for the story did not establish that enlicitide reduces heart attacks, strokes, cardiovascular deaths or deaths from any cause. The approval was based on LDL-C lowering, not cardiovascular outcomes.

Is oral enlicitide better than injectable PCSK9 treatments?

The approval studies compared enlicitide with placebo and did not show that it works better than another nonstatin medicine. Injectable PCSK9 treatments have cardiovascular outcomes evidence that cannot be assumed to apply to enlicitide.

References

1. FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults With High Cholesterol — US Food and Drug Administration, 2026
2. Efficacy and Safety of an Oral PCSK9 Inhibitor, MK-0616, in Hypercholesterolemia — Journal of the American College of Cardiology, 2023
3. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease — The New England Journal of Medicine, 2017
4. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome — The New England Journal of Medicine, 2018